Fig 1.
Uterine weights are shown in box graphs. Values are expressed as the mean ± SD, n = 5–7 for each group, ANOVA, Tukey-Kramer *p<0.05 (in black): the topical EB wound treatment group versus the subcutaneous E2 pellet group, *p<0.05 (in red): the topical EB wound treatment group versus the topical E2 skin application group, ☨p<0.05: versus OVX.
Fig 2.
(A) Wounds that were 4 mm in diameter were inflicted and healing was recorded by photography. Bar, 5 mm. (B) Ratios of wound areas to the initial area on day 0 are shown on line graphs for each day. Values are expressed as the mean ± SD, n = 10, ANOVA, Tukey-Kramer *p<0.05 (in black): the topical EB wound treatment group versus the subcutaneous E2 pellet group, *p<0.05 (in red): the topical EB wound treatment group versus the topical E2 skin application group.
Fig 3.
(A) The number of neutrophils per mm2 and (B) number of macrophages per mm2 are shown in box graphs. Values are expressed as the mean ± SD, n = 5–6 for each group, ANOVA, Tukey-Kramer *p<0.05 (in black): the topical EB wound treatment group versus the subcutaneous E2 pellet group, *p<0.05 (in red): the topical EB wound treatment group versus the topical E2 skin application group. (C) Neutrophils (arrows) stained with an anti-neutrophil antibody and macrophages (arrows) stained with an anti-Mac-3 antibody were observed in wound tissue on day 7. Bar, 20 μm.
Fig 4.
New blood vessels and wound contraction.
(A) The number of new blood vessels per mm2 and (B) ratio of myofibroblasts (%) are shown in box graphs. Values are expressed as the mean ± SD, n = 5–6 for each group, ANOVA, Tukey-Kramer *p<0.05 (in black): the topical EB wound treatment group versus the subcutaneous E2 pellet group, *p<0.05 (in red): the topical EB wound treatment group versus the topical E2 skin application group. (C) New blood vessels stained with an anti-CD31 antibody (bars, 50 μm) and myofibroblasts (arrows) stained with an anti-α-SMA antibody (bars, 200 μm) were observed in granulation tissue on day 7.